Pefloxacin and ciprofloxacin are two new quinoline carboxylic acid derivatives that have activity in vitro against a wide range of gram-negative bacteria, including Pseudomonas aeruginosa. Using a well-standardized model of Pseudomonas pneumonia in neutropenic guinea pigs, we tested the efficacy in vivo of these new agents. Both were highly effective in increasing survival and decreasing bacterial counts in the lungs of surviving animals. Pefloxacin and ciprofloxacin were significantly better (P < 0.05) than aminoglycosides or beta-lactams tested in prior studies with this model, and they were as effective as combination therapy with aminoglycosides and beta-lactams. Resistance to either ciprofloxacin or pefloxacin did not emerge during the study period. Further studies with these drugs in the therapy of Pseudomonas sp. infections are warranted.
,ug/ml for many of the above-mentioned bacteria (2, 5, 14) . It is of special interest that both of these antimicrobial agents are highly active against Pseudomonas aeruginosa, including multiply drug-resistant strains (2, 11) .
The purpose of this study was to examine the effectiveness of pefloxacin and ciprofloxacin against induced P. aeruginosa pneumonia in neutropenic guinea pigs.
MATERIALS AND METHODS
Ciprofloxacin was obtained from Miles Pharmaceuticals, West Haven, Conn. Pefloxacin mesylate was obtained from Rhone-Poulenc, Paris, France.
The MIC of each agent for the P5 strain of P. aeruginosa was determined in Mueller-Hinton broth supplemented with Mg2+ and Ca2+ by the macro-tube dilution method, using a standard inoculum of 5 log10 CFU/ml (13) . The MBC was defined as the lowest concentration of drug that killed 99.9% of the original inoculum.
Time-kill studies were performed with each antimicrobial agent, using concentrations which approximated the serum concentrations at peak levels. Logarithmic-phase organisms were added to supplemented Mueller-Hinton broth containing 12 ,ug of pefloxacin per ml, 4 ,ug of ciprofloxacin per ml, or no antibiotic and were incubated at 35°C. Samples were removed and quantitatively cultured before and after 4, 8, and 24 h of incubation.
To determine the serum half-life (t412) of each drug and develop the therapeutic regimens, preliminary drug dosing studies were performed in groups of five normal guinea pigs. (4) . The doses chosen for use in the study and the estimated half-lives and the respective peak (1 h) and trough (12 h) serum concentrations are given below.
The experimental animal model used in these studies will only be outlined here since it has been described in detail elsewhere (9) . Hartley strain guinea pigs (400 to 500 g) were rendered leukopenic by daily injections of cyclophosphamide (60 mg/kg intraperitoneally) for 6 days and, at the time of inoculation, had peripheral leukocyte counts of <1,000/mm3. Pneumonias were induced by intratracheal instillation of 103 CFU of P. aeruginosa (P-5). Sixteen hours after inoculation, the animals had developed a bilateral hemorrhagic pneumonia with approximately 105 CFU of P. aeruginosa per g of lung tissue, at which time animals were randomly distributed to two treatment and one control group.
Pefloxacin and ciprofloxacin were each administered at a dose of 25 mg/kg every 12 h. After 36 h, surviving animals were sacrificed via intraperitoneal injection of sodium pentobarbital. Lungs were removed aseptically and homogenized in 20 ml of saline. The homogenate was quantitatively streaked on blood agar plates which were incubated overnight at 35°C. Therapeutic efficacy was judged by both animal survival and numbers of bacteria in the lungs of animals that survived. Organisms recovered from the blood agar plates of the lung homogenates were tested for susceptibility (MIC) of the relevant therapeutic agents (1).
RESULTS
The MIC and MBC of pefloxacin for the test strain of P. aeruginosa were 1 and 4 ,ug/ml, respectively. The MIC and MBC of ciprofloxacin for this same organism were both 1 ,ug/ml.
Both pefloxacin and ciprofloxacin were rapidly active against this strain in in vitro time-kill studies (Fig. 1) Six animals were sacrificed 16 h after inoculation just before therapy, to document the presence of a well-established pneumonia. At this time there were 4.9 ± 0.5 (mean ± standard deviation) log10 CFU of P. aeruginosa per g of lung (Table 1 ). All recipients of pefloxacin survived, as did 16 of 17 recipients of ciprofloxacin. In contrast, 15 of the 16 untreated controls died during the experiment. Both pefloxacin and ciprofloxacin were highly effective in reducing the number of viable organisms in the lungs (<2.0 log10 CFU/g). Only three recipients of pefloxacin had positive lung cultures. The MICs for isolates from guinea pigs treated with pefloxacin were not different from that of the original inoculum. None of the recipients of ciprofloxacin sacrificed at 36 h had positive lung cultures. The one animal in this treatment group that died during therapy was not examined for the development of resistance.
DISCUSSION
Pefloxacin and ciprofloxacin are highly active in vitro against P. aeruginosa (MIC90, s2 and .1 ,ug/ml, respectively). Serum concentrations above this level have been obtained in humans by oral drug administration (3, 6) . Therefore, these new quinolones should prove to be effective in the therapy of systemic infections caused by this organism. Montay and associates have shown that pefloxacin concentrates in the lungs of rats and dogs at levels more than twice the simultaneous serum level, giving it an advantage in the therapy of Pseudomonas pneumonia (6).
Schiff et al. recently reported on the efficacy of ciprofloxacin in treating Pseudomonas pneumonia in nonneutropenic guinea pigs (10) . They found ciprofloxacin to be as effective as tobramycin and more effective than ticarcillin in improving early bacterial killing and long-term survival. Our study confirms the effectiveness of ciprofloxacin and pefloxacin in the therapy of established pulmonary infections in a neutropenic host. In our model, therapy was initiated 16 h after infection as compared to 15 min in the study by Schiff et al.
The effectiveness of these two agents is striking when the results are compared with those from prior studies with aminoglycosides and beta-lactams in this same model (9) . Those studies were carried out under identical experimental conditions, with the same test organism, controlling for initial bacterial inoculum, lung titers at initiation of therapy, and outcome for uninfected animals. In those studies, lung titers of animals treated with single agents ranged from 4.0 to 6.3 log1o CFU per g of lung tissue (tobramycin, 4.2 ± 1.4; netilmicin, 6.3 ± 0.8; ticarcillin, 4.0 ± 0.5; and ceftazidime, 4.4 ± 1.0). Synergistic aminoglycoside-beta-lactam combinations were more effective, with bacterial titers ranging from 2.1 to 3.2 log1o CFU per g of lung tissue (tobramycinticarcillin, 2.5 ± 0.6; ceftazidime-tobramycin, 2.1 ± 0.3; and ceftazidime-netilmicin, 3.2 ± 1.0). By this retrospective comparison, pefloxacin and ciprofloxacin were more effective than any other single antimicrobial agent and as effective as the combinations tested.
The marked efficacy of pefloxacin and ciprofloxacin in vivo in the absence of a normal complement of leukocytes may relate to their rapid killing as demonstrated by the in vitro time-kill curves. Reeves et al. demonstrated rapid killing in vitro of both logarithmic-and stationary-phase organisms by ciprofloxacin (8) . Clinical studies have demonstrated the importance of a rapid bactericidal effect in the treatment of gram-negative bacillary infections in the neutropenic host (16) .
Repeated passage of susceptible organisms in media containing subinhibitory concentrations of ciprofloxacin has resulted in selection of resistant variants (8) . We did not isolate drug-resistant strains from lung tissue after 36 h of therapy with pefloxacin; however, whether the emergence of drug-resistant bacteria will become a problem with either pefloxacin or ciprofloxacin will depend on further in vivo studies.
P. aeruginosa is a major cause of pneumonia in immunosuppressed and hospitalized patients (7). Aminoglycosides and beta-lactams, either as single agents or in combination therapy, have been the mainstay for treatment of Pseudomonas sp. infections. Not all patients are able to tolerate these antibiotics, either because of drug allergies or due to adverse antibiotic effects such as renal impairment. In addition, some strains of Pseudomonas sp. have become increasingly resistant to these drugs. The quinolones represent a new class of antimicrobial agents shown to be highly effective in vitro against Pseudomonas sp. We have demonstrated the in vivo efficacy of pefloxacin and ciprofloxacin in 
